Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2017 16:05 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights

Q3 Cash Balance of $113.6M – Cash through Q3 2019 Continued progress on the advancement of key clinical programs including GITRL-Fc Phase 1 initiation Management to Host Conference Call/Webcast this...
September 13, 2017 08:05 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial

REDWOOD CITY, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
April 05, 2017 08:00 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Highlights New Data Presented at the American Association for Cancer Research Annual Meeting 2017

WASHINGTON and REDWOOD CITY, Calif., April 05, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing...
April 19, 2016 09:00 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016

REDWOOD CITY, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the...
March 16, 2016 16:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed to Present Data at the American Association of Cancer Research Annual Meeting 2016

REDWOOD CITY, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and...